Anteris Technologies: Launches $35m capital raise as FDA approves DurAVR study

Anteris Technologies Launches $35m capital raise as FDA approves DurAVR study

• Anteris Technologies (AVR) launches a $35 million capital raise for the clinical development of its DurAVR transcatheter heart valve (THV) system
• The company also received expanded FDA approval for an early feasibility study (EFS) assessing the DurAVR THV system in subjects with severe aortic stenosis
• Anteris CEO Wayne Peterson says the removal of prior study conditions by the FDA will pave the way for the company’s “ground-breaking technology”
• The capital raise will go towards funding DurAVR development and also providing general working capital
• AVR shares are down 4.7 per cent, trading at $22.91 at 2:50 pm AEDT